Hepatitis C infection in HIV-1 natural viral suppressors.
OBJECTIVE
HIV-1 natural viral suppressors (NVSs) demonstrate an intrinsic ability to control HIV-1 replication in the absence of antiretroviral therapy. The objective of this study was to investigate whether HIV-infected NVSs also demonstrate enhanced ability to control hepatitis C virus (HCV) infection, and whether HCV infection in the NVSs affects the degree of HIV control.


METHODS
A cross-sectional study was undertaken to compare HCV-related parameters in the NVS to the two race-matched cohorts (HIV/HCV-coinfected or HCV-monoinfected patients). Within the NVS, HIV-related parameters were compared based on the presence or absence of chronic HCV.


RESULTS
NVS patients had a significantly higher clearance rate of HCV at 23.3% (seven of 30), compared to the 6.5% (23 of 350) of HIV/HCV-coinfected and 9.1% (32 of 350) of HCV-monoinfected patients (P = 0.005 and P = 0.024, respectively). Apart from the HCV clearance rate, there was no significant difference in HCV-related parameters such as HCV viral load or liver histology in the NVS with chronic HCV compared to HCV/HIV-coinfected patients or HCV-monoinfected patients. However, NVS patients with chronic HCV infection had statistically significant lower CD4 cell count and CD4%, and lower CD4/CD8 ratio compared to those NVSs without chronic HCV infection (P = 0.029, P = 0.046, and P = 0.062, respectively).


CONCLUSIONS
It appears that some NVS patients have the ability to effectively control multiple agents that can cause chronic viral infections. In addition, it appears that the presence of chronic HCV infection within the NVS adversely affects immunological parameters.
Sajadi
Mohammad M
MM
Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. msajadi@ihv.umaryland.edu
Shakeri
Nahzinine
N
Talwani
Rohit
R
Redfield
Robert R
RR
D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000276:immunology / Q000821:virology*; D020276:HIV Long-Term Survivors; D015497:HIV-1 / Q000302:isolation & purification / Q000502:physiology*; D016174:Hepacivirus / Q000302:isolation & purification / Q000502:physiology; D006526:Hepatitis C / Q000150:complications / Q000276:immunology / Q000821:virology*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000276:immunology / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D019562:Viral Load; D014779:Virus Replication
J Virol. 2006 May;80(10):4758-70
16641269
JAMA. 2002 Jul 10;288(2):199-206
12095384
AIDS. 2007 Feb 19;21(4):517-9
17301571
J Infect Dis. 2009 Sep 15;200(6):984-90
19656066
Virology. 1998 May 10;244(2):504-12
9601518
Hepatology. 1999 Oct;30(4):1054-8
10498659
Clin Infect Dis. 2009 Aug 15;49(4):612-22
19591597
AIDS. 1995 Oct;9(10):1131-6
8519448
J Infect Dis. 1996 Oct;174(4):690-5
8843204
J Infect Dis. 2007 Nov 15;196(10):1474-82
18008226
AIDS Res Hum Retroviruses. 2007 Jul;23(7):863-7
17678468
J Infect Dis. 2008 Feb 15;197(4):563-71
18275276
Hepatology. 2001 Dec;34(6):1193-9
11732009
Clin Infect Dis. 2006 Nov 1;43(9):1209-12
17029144
Lancet. 2000 Nov 25;356(9244):1800-5
11117912
Gut. 2006 Aug;55(8):1183-7
16434426
AIDS. 2002 Apr 12;16(6):813-28
11919483
Arch Intern Med. 2002 Oct 14;162(18):2125-32
12374521
Clin Infect Dis. 2005 Oct 1;41(7):1053-6
16142675
JAMA. 2000 Jul 26;284(4):450-6
10904508
Can J Gastroenterol. 2007 Jul;21(7):447-51
17637948
J Viral Hepat. 2006 Jan;13(1):34-41
16364080
Clin Infect Dis. 2001 Aug 15;33(4):562-9
11462196
Nature. 2009 Oct 8;461(7265):798-801
19759533
J Infect Dis. 2009 Oct 15;200(8):1216-26
19764883
J Clin Virol. 2007 Jun;39(2):82-6
17434339
J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):403-8
19214118
Clin Infect Dis. 2007 Feb 1;44(3):431-7
17205454
J Med Virol. 2007 May;79(5):503-10
17385690
Vox Sang. 1995;69(3):259-60
8578743